Cooper Companies, Inc. (COO)

Over the past six months, The Cooper Companies' stock price has experienced a notable decline, underperforming both the broader market and the healthcare sector. The stock saw a 22.55% decrease over this period and hit a 52-week low of $67.33 on May 30, 2025. Key events impacting the stock include Q4 2024 earnings where adjusted EPS surpassed analyst estimates, but revenues marginally missed expectations, leading to a stock drop of over 1%. In Q1 2025 earnings, the company's EPS met market expectations, but revenues were slightly below forecasts, resulting in a 4.92% drop in after-hours trading. Cooper Companies reported earnings that exceeded expectations and revenue slightly above anticipated figures in Q2 2025 earnings, however, the stock still declined in aftermarket trading, partly due to downward revisions in growth expectations for the contact lens and fertility markets. On May 30, 2025, JP Morgan downgraded Cooper Companies' stock from "Overweight" to "Neutral" and reduced its price target, reflecting concerns over mixed financial results and market challenges. Conversely, on June 17, 2025, Needham upgraded its outlook for Cooper Companies from "Hold" to "Buy."

Demand for The Cooper Companies' products and services generally follows seasonal trends, with the fiscal first and second quarters typically experiencing a lighter start. The company has seen strong demand for specific products, such as its MyDay daily silicone hydrogel lenses and MiSight myopia management lenses. Fertility sales are also expected to maintain high single-digit growth throughout the fiscal year. However, supply constraints for MyDay lenses have been a limiting factor in meeting demand. Sales growth was anticipated to decelerate in the first half of fiscal 2025, partly due to the impact of the prior back-to-school season and U.S. inventory reductions affecting myopia management sales.

The Cooper Companies, Inc. operates primarily in the medical device sector, specifically within the ophthalmology and surgical markets, falling under the medical equipment and supplies industry. The company is structured into two main business units: CooperVision and CooperSurgical. CooperVision focuses on the design, production, and distribution of contact lenses, including single-use, two-week, and monthly lenses that address various eye conditions. CooperSurgical provides products for fertility and women's health, encompassing ART devices, needles, catheters, micropipettes, the Paragard Intrauterine Copper Contraceptive, and surgical products.

The Cooper Companies, Inc. maintains a significant global presence, with operations spanning the Americas, Europe, Asia, and Africa. The company has manufacturing, cryostorage, research and development, and distribution facilities worldwide, serving customers in approximately 130 countries. Its corporate headquarters are located in San Ramon, California, USA.

In the past year, The Cooper Companies has actively highlighted its commitment to sustainability, publishing its 2024 Sustainability Report on May 20, 2025, showcasing initiatives aimed at reducing plastic usage, achieving sustainability certifications, and investing significantly in employee development programs. The report aligns with Sustainability Accounting Standards Board (SASB) Standards, demonstrating a focus on investor-oriented sustainability reporting. There is no readily available information indicating specific negative events that have significantly impacted The Cooper Companies' brand reputation in the past year.

The ownership of The Cooper Companies, Inc. is predominantly institutional, with institutional shareholders holding 97.74% of the stock. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., State Street Corp, Kayne Anderson Rudnick Investment Management Llc, Capital World Investors, and T. Rowe Price Investment Management, Inc. Individual insiders hold 1.19% of the stock, and retail investors hold 1.07%.